A5036433757- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
- Systemic Lupus Erythematosus Research
- Hemoglobinopathies and Related Disorders
- Erythropoietin and Anemia Treatment
- Dialysis and Renal Disease Management
- Complement system in diseases
- COVID-19 and healthcare impacts
- Diagnosis and treatment of tuberculosis
- Vasculitis and related conditions
- Platelet Disorders and Treatments
- Apelin-related biomedical research
- Advanced Causal Inference Techniques
- Liver Disease and Transplantation
- Inflammatory Bowel Disease
- Blood Coagulation and Thrombosis Mechanisms
- Tuberculosis Research and Epidemiology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Healthcare cost, quality, practices
- Atherosclerosis and Cardiovascular Diseases
- Diabetes Treatment and Management
- Iron Metabolism and Disorders
- Renal Transplantation Outcomes and Treatments
Provincial Health Services Authority
2019-2024
University of British Columbia
2023
BC Cancer Agency
2022
The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate and how combine them with other clinical variables are currently unknown.
Background and objectives Social deprivation is a recognized risk factor for undifferentiated CKD; however, its association with glomerular disease less well understood. We sought to investigate the relationship between socioeconomic position population-level incidence of biopsy-proven diseases. Design, setting, participants, & measurements In this retrospective cohort study, provincial kidney pathology database (2000–2012) was used capture all incident cases membranous nephropathy ( n...
Despite recognized geographic and sex-based differences in hemoglobin the general population, these factors are typically ignored patients with chronic kidney disease (CKD) whom a single therapeutic range for is recommended. We sought to compare distribution of across international nondialysis CKD populations evaluate predictors hemoglobin.
Patients with glomerular disease are at high risk of cardiovascular but the contribution immunosuppression to this is unclear. In retrospective cohort study 1912 patients (comprised 759 IgA nephropathy, 540 focal segmental glomerulosclerosis, 387 membranous nephropathy and 226 minimal change disease) from British Columbia, Canada, we evaluated association between exposure specific immunosuppressive medications a composite outcome including coronary artery, cerebrovascular peripheral arterial...
BACKGROUND: Albuminuria is a marker of chronic kidney disease (CKD) associated with an increased risk end-stage (ESKD) and mortality in the general population, but it uncertain whether same association exists liver transplant (LT) recipients. This study examined between albuminuria failure LT recipients.METHODS: Retrospective cohort 294 adults who received January 1, 1989, December 31, 2011, British Columbia, Canada. Cox multivariable regression was used to determine ACR primary combined...
The population-level incidence and epidemiology of glomerulonephritis (GN) is not well studied. Although the all-cause chronic kidney disease associated with lower socioeconomic (SES) status, it currently known if this also applies to specific types GN. We therefore investigated relationship between SES membranous nephropathy (MN), IgA (IgAN), focal segmental glomerulosclerosis (FSGS), ANCA-related GN lupus nephritis (LN) in a large Canadian province.